Musculoskeletal and joint diseases recommendations
On this page you will find our recommendations sorted by BNF chapter.
Appraisal Reports are available to stakeholders on request.
Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary on nuth.nyrdtc.rxsupp@nhs.net
| Title | Documents | Decision | Date | |
|---|---|---|---|---|
|
Updated 22/02/2022 |
Actipatch® for management of localised musculoskeletal pain | Recommendation | Not recommended | 22/02/2022 |
| Etanercept Biosimilar (Benepali®) | Recommendation | Recommended as a 1st line option | 05/04/2016 | |
| Extracorporeal shockwave therapy for plantar fasciitis (NETAG) | Recommendation | Not recommended | 10/07/2012 | |
| Infliximab biosimilars | Recommendation | Recommended as an option | 02/06/2015 | |
|
Updated 22/02/2022 |
Infliximab Subcutaneous (Remsima®) | Recommendation | Recommended as an option during Covid-19 Pandemic. | 22/02/2022 |
| Orthotic functional electrical stimulation (FES) for drop foot of neurological origin (updated) | Recommendation | Recommended if patient fulfils specific criteria | 08/09/2015 | |
| Rituximab (MabThera®) for severe rheumatoid arthritis (non-NICE indications) (NETAG) | Recommendation | Recommends rituximab in combination with methotrexate as first-line biological therapy in cases where there is an absolute contraindication to tumour necrosis factor inhibitor | 11/10/2011 | |
| Rituximab Biosimilars | Recommendation | Approved for use as an option. | 06/06/2017 | |
| Sequential use of TNF inhibitors for the treatment of Psoriatic Arthritis | Recommendation | Recommended as an option | 08/09/2015 |